Compile Data Set for Download or QSAR
Report error Found 30 Enz. Inhib. hit(s) with all data for entry = 11726
TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642790(US11857552, Compound APPAMP-004)
Affinity DataIC50: 4.20nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642790(US11857552, Compound APPAMP-004)
Affinity DataIC50: 4.20nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642790(US11857552, Compound APPAMP-004)
Affinity DataIC50: 4.20nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642789(US11857552, Compound APPAMP-003)
Affinity DataIC50: 8.90nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642789(US11857552, Compound APPAMP-003)
Affinity DataIC50: 8.90nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642789(US11857552, Compound APPAMP-003)
Affinity DataIC50: 8.90nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642787(US11857552, Compound APPAMP-001)
Affinity DataIC50: 13nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642787(US11857552, Compound APPAMP-001)
Affinity DataIC50: 13nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642787(US11857552, Compound APPAMP-001)
Affinity DataIC50: 13nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642789(US11857552, Compound APPAMP-003)
Affinity DataIC50: 22nMAssay Description:CDK9 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:Human CDK9/cycK (Promega, V4104).CDKtide (SignalChem, C06-58).Ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642788(US11857552, Compound APPAMP-002)
Affinity DataIC50: 33nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642788(US11857552, Compound APPAMP-002)
Affinity DataIC50: 33nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642788(US11857552, Compound APPAMP-002)
Affinity DataIC50: 33nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM50526797(Ct-7001 | Ct7001 | ICEC-0942 | ICEC0942 | Samuraci...)
Affinity DataIC50: 34nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM50526797(Ct-7001 | Ct7001 | ICEC-0942 | ICEC0942 | Samuraci...)
Affinity DataIC50: 34nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetCyclin-dependent kinase 7(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM50526797(Ct-7001 | Ct7001 | ICEC-0942 | ICEC0942 | Samuraci...)
Affinity DataIC50: 34nMAssay Description:CDK7 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:CDK7/cycH/MAT1 (ProQinase, 0366-0360-4).MnCl2 (Sigma, M1787).CDKt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetCyclin-dependent kinase 9(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642790(US11857552, Compound APPAMP-004)
Affinity DataIC50: 130nMAssay Description:CDK9 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:Human CDK9/cycK (Promega, V4104).CDKtide (SignalChem, C06-58).Ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642789(US11857552, Compound APPAMP-003)
Affinity DataIC50: 190nMAssay Description:CDK2 IC50 Materials and solutions:HEPES (Sigma, H3375).Sodium orthovanadate (Sigma, 450243).DTT (Sigma).MgCl2 (Sigma, M1028).PEG-20000 (Sigma, 95172)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642789(US11857552, Compound APPAMP-003)
Affinity DataIC50: 190nMAssay Description:CDK2 IC50 Materials and solutions:HEPES (Sigma, H3375).Sodium orthovanadate (Sigma, 450243).DTT (Sigma).MgCl2 (Sigma, M1028).PEG-20000 (Sigma, 95172)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642787(US11857552, Compound APPAMP-001)
Affinity DataIC50: 200nMAssay Description:CDK9 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:Human CDK9/cycK (Promega, V4104).CDKtide (SignalChem, C06-58).Ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642788(US11857552, Compound APPAMP-002)
Affinity DataIC50: 210nMAssay Description:CDK9 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:Human CDK9/cycK (Promega, V4104).CDKtide (SignalChem, C06-58).Ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM50526797(Ct-7001 | Ct7001 | ICEC-0942 | ICEC0942 | Samuraci...)
Affinity DataIC50: 320nMAssay Description:CDK9 IC50 Materials and Solutions:In addition to those mentioned above for Method 1:Human CDK9/cycK (Promega, V4104).CDKtide (SignalChem, C06-58).Ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642787(US11857552, Compound APPAMP-001)
Affinity DataIC50: 640nMAssay Description:CDK2 IC50 Materials and solutions:HEPES (Sigma, H3375).Sodium orthovanadate (Sigma, 450243).DTT (Sigma).MgCl2 (Sigma, M1028).PEG-20000 (Sigma, 95172)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642787(US11857552, Compound APPAMP-001)
Affinity DataIC50: 640nMAssay Description:CDK2 IC50 Materials and solutions:HEPES (Sigma, H3375).Sodium orthovanadate (Sigma, 450243).DTT (Sigma).MgCl2 (Sigma, M1028).PEG-20000 (Sigma, 95172)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM50526797(Ct-7001 | Ct7001 | ICEC-0942 | ICEC0942 | Samuraci...)
Affinity DataIC50: 660nMAssay Description:CDK2 IC50 Materials and solutions:HEPES (Sigma, H3375).Sodium orthovanadate (Sigma, 450243).DTT (Sigma).MgCl2 (Sigma, M1028).PEG-20000 (Sigma, 95172)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetCyclin-dependent kinase 2(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM50526797(Ct-7001 | Ct7001 | ICEC-0942 | ICEC0942 | Samuraci...)
Affinity DataIC50: 660nMAssay Description:CDK2 IC50 Materials and solutions:HEPES (Sigma, H3375).Sodium orthovanadate (Sigma, 450243).DTT (Sigma).MgCl2 (Sigma, M1028).PEG-20000 (Sigma, 95172)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetCyclin-dependent kinase 2(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642788(US11857552, Compound APPAMP-002)
Affinity DataIC50: 770nMAssay Description:CDK2 IC50 Materials and solutions:HEPES (Sigma, H3375).Sodium orthovanadate (Sigma, 450243).DTT (Sigma).MgCl2 (Sigma, M1028).PEG-20000 (Sigma, 95172)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642788(US11857552, Compound APPAMP-002)
Affinity DataIC50: 770nMAssay Description:CDK2 IC50 Materials and solutions:HEPES (Sigma, H3375).Sodium orthovanadate (Sigma, 450243).DTT (Sigma).MgCl2 (Sigma, M1028).PEG-20000 (Sigma, 95172)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642790(US11857552, Compound APPAMP-004)
Affinity DataIC50: 2.40E+3nMAssay Description:CDK2 IC50 Materials and solutions:HEPES (Sigma, H3375).Sodium orthovanadate (Sigma, 450243).DTT (Sigma).MgCl2 (Sigma, M1028).PEG-20000 (Sigma, 95172)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Carrick Therapeutics

US Patent
LigandPNGBDBM642790(US11857552, Compound APPAMP-004)
Affinity DataIC50: 2.40E+3nMAssay Description:CDK2 IC50 Materials and solutions:HEPES (Sigma, H3375).Sodium orthovanadate (Sigma, 450243).DTT (Sigma).MgCl2 (Sigma, M1028).PEG-20000 (Sigma, 95172)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent